Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 17/20 | 0.67 |
| ▸ | HRH1 | P35367 | 3/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3638623 | 0.91 | SSTR5 (0.67) | SSTR5HRH1HTR2B | |
| SCHEMBL3634902 | 0.90 | SSTR5 (0.67) | SSTR5HRH1HTR2BSSTR1 | |
| SCHEMBL3634850 | 0.90 | SSTR5 (0.67) | SSTR5HRH1HTR2B | |
| SCHEMBL3632207 | 0.88 | SSTR5 (0.66) | SSTR5HRH1HTR2BSSTR1 | |
| SCHEMBL3636558 | 0.88 | SSTR5 (0.66) | SSTR5HRH1HTR2BSSTR1 | |
| SCHEMBL3636110 | 0.81 | SSTR5 (0.69) | SSTR5HRH1HTR2B | |
| SCHEMBL5007370 | 0.81 | SSTR5 (0.69) | SSTR5HRH1HTR2B | |
| SCHEMBL5009639 | 0.81 | SSTR5 (0.47) | SSTR5HRH1HTR2BSSTR1 | |
| SCHEMBL3781123 | 0.81 | SSTR5 (0.61) | SSTR5HRH1HTR2BSSTR1KDM4E | |
| SCHEMBL3572493 | 0.80 | SSTR5 (1.00) | SSTR5HRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155718-A2 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | claimed |
| WO-2008148710-A2 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF SOMATOSTATINS RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-11 | — | — | WO | claimed |
| US-20080306116-A1 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | claimed |
| US-20080306116-A1 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306116-A1 | ARYLOXAZOLE, ARYLOXADIAZOLE AND BENZIMIDAZOLE DERIVATIVES | SSTR5, NPY5R, SSTR3 | SSTR5 1/4885HRH1 207/4885HTR2B 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.